Marked decrease of apolipoprotein A-V in both diabetic and nondiabetic patients with end-stage renal disease.

Area of Science:

• Lipid metabolism
• Renal disease research
• Cardiovascular disease risk factors

Background:

• Apolipoprotein A-V (apo A-V) influences plasma triglyceride (TG) levels.
• End-stage renal disease (ESRD) is linked to elevated TG and cardiovascular disease.
• The role of apo A-V in ESRD-related hypertriglyceridemia requires investigation.

Purpose of the Study:

• To measure plasma apo A-V levels in diabetic and nondiabetic ESRD patients.
• To explore the association between apo A-V levels and hypertriglyceridemia in ESRD.
• To investigate the potential role of reduced apo A-V in ESRD pathogenesis.

Main Methods:

• Plasma apo A-V levels were quantified using enzyme-linked immunosorbent assay (ELISA).
• Measurements were performed on 70 ESRD patients (diabetic and nondiabetic) and 20 controls.
• Statistical analyses correlated apo A-V with TG and high-density lipoprotein cholesterol (HDL-C).

Main Results:

• ESRD patients exhibited significantly reduced apo A-V levels (40-44% of controls).
• Plasma TG was elevated in diabetic ESRD patients; HDL-C was lower in all ESRD patients.
• Apo A-V levels did not correlate with TG overall but positively correlated with HDL-C.

Conclusions:

• Reduced apo A-V levels are a consistent finding in ESRD patients.
• Low apo A-V may not be the primary driver of hypertriglyceridemia in all ESRD cases.
• Further research is needed to clarify the specific role of low apo A-V in diabetic ESRD-associated hypertriglyceridemia.